To investigate if radium-223 increases peripheral immune responses to sipuleucel-T in men with bone-predominant, minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
32 patients were randomized 1:1 in this open label, phase 2 multicenter trial.